Objective To evaluate the curative effect and safety of voriconazole in the treatment of pediatric hematological malignancies complicated with invasive fungal infection. Methods A total of 46 children of hematological malignancies complicated with invasive fungal infection received voriconazole for treatment. The severe cases received load dosage of 6 mg/(kg·time), q.12 h. at the first day, and then received maintenance dose of 4 mg/(kg·time), q.12 h. from the next day on. The mild cases were treated by oral administration of voriconazole by 200 mg, q.12 h. for 14~42 d of sequential therapy. Curative effects were observed. Results The effective rate of voriconazole was 67.4%. There were only a few children with the adverse effect as liver dysfunction, gastrointestinal react, and paropsis. Conclusion Voriconazole has good effect in the treatment of pediatric hematological malignancies complicated with invasive fungal infection with few toxic and side effect. It is an effective and safe antifungal drug, which is worth clinical promotion.%目的：评价伏立康唑治疗儿童血液系统恶性肿瘤伴发侵袭性真菌感染的疗效及安全性。方法46例血液系统恶性肿瘤伴发侵袭性真菌感染的患儿,给予伏立康唑治疗。重症者首日予以负荷剂量6 mg/(kg·次), q.12 h.,次日起给予维持剂量4 mg/(kg·次), q.12 h.；轻症者给予伏立康唑片口服,剂量为200 mg, q.12 h.,序贯治疗14~42 d。观察疗效。结果伏立康唑有效率为67.4%,只有少数患儿出现轻度肝功能损害、胃肠道反应、视觉异常等不良反应。结论伏立康唑治疗儿童血液系统恶性肿瘤伴发侵袭性真菌感染效果好,毒副作用少,是一种安全高效的抗真菌药物,值得临床推广。
展开▼
